Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 114870-03-0] Fondaparinux sodium

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B0597
Brand:	MCE
CAS:	114870-03-0

Overview

MDL	MFCD06794972
Molecular Weight	1728.08
Molecular Formula	C31H43N3Na10O49S8
SMILES	O[C@H]([C@@H](O)[C@@H]1O[C@](O[C@H](COS(=O)(O[Na])=O)[C@@H](O)[C@@H]2O)([H])[C@@H]2NS(=O)(O[Na])=O)[C@](O[C@@H]1C(O[Na])=O)([H])O[C@H]([C@H](O[C@@H]3O[C@]([C@@H]4O)([H])[C@@H](O[C@@H](O[C@]([C@@H]5O)([H])[C@H](O[C@H](OC)[C@@H]5NS(=O)(O[Na])=O)COS(=O)(O[Na])=O)[C@@H]4OS(=O)(O[Na])=O)C(O[Na])=O)COS(=O)(O[Na])=O)[C@@H]([C@H]3NS(=O)(O[Na])=O)OS(=O)(O[Na])=O

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

[1]Adv Sci (Weinh). 2022 Oct 18;e2203088.
[2]Sens Actuators B Chem. 21 September 2022, 132709.
[3]Patent. US20230012702A1.

Summary

Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.

IC50 & Target

Factor Xa ^[1]

In Vitro

Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. For Fondaparinux, its IC ₅₀ values (anti-Xa IU/ml) are 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs) ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01121770	Duke University\|GlaxoSmithKline	Renal Insufficiency	May 2010	Phase 1
NCT00333021	GlaxoSmithKline	Venous Thromboembolism	May 2006	Phase 3
NCT00060554	Schering-Plough	Myocardial Infarction\|Coronary Disease	April 2003	Phase 2
NCT00038961	GlaxoSmithKline\|Sanofi	Thromboembolism	November 2001	Phase 3
NCT00378027	The Cleveland Clinic\|GlaxoSmithKline	Pulmonary Embolism	August 2006
NCT00767559	The New England Baptist Hospital	Pulmonary Embolism	November 2008	Not Applicable
NCT00474591	Hamilton Health Sciences Corporation\|GlaxoSmithKline\|McMaster University	Coronary Bypass Graft Failure+Occlusion		Phase 3
NCT04359212	Quovadis Associazione\|Azienda Ospedaliera di Padova	COVID-19 Disease\|Thromboembolism, Venous	May 1, 2020
NCT00320398	GlaxoSmithKline	Thrombosis, Venous	January 30, 2006	Phase 3
NCT01444612	GlaxoSmithKline	Thrombosis, Venous	February 2010
NCT00789399	Prairie Education and Research Cooperative\|American College of Phlebology	Deep Vein Thrombosis\|Coronary Artery Bypass Surgery\|Venous Thromboembolism	November 19, 2009	Not Applicable
NCT00981409	GlaxoSmithKline	Embolism, Pulmonary	July 2007	Phase 3
NCT01727401	G. d´Annunzio University	Medical Patient\|Thrombocytopenia	November 2012	Phase 4
NCT01428531	GlaxoSmithKline	Ataxia	January 2012
NCT00464087	Medstar Health Research Institute\|GlaxoSmithKline	Acute Coronary Syndromes	June 2007	Phase 3
NCT00909064	Paul Di Cesare,MD\|University of California, Davis	Total Knee Replacement	June 2009	Phase 4
NCT00377091	University of Minnesota\|GlaxoSmithKline	Pulmonary Embolism	June 2007	Phase 4
NCT00659399	NYU Langone Health\|GlaxoSmithKline	Ovarian Carcinoma	January 2008	Phase 1
NCT00603824	Methodist Healthcare\|University of Tennessee	Heparin-Induced Thrombocytopenia	January 2008	Phase 4
NCT00064428	GlaxoSmithKline\|Sanofi	Thromboembolism	August 2003	Phase 3
NCT01064362	GlaxoSmithKline	Thrombosis, Venous	January 2010
NCT00881088	Red Cross Hospital Beverwijk	Deep Vein Thrombosis\|Pulmonary Embolism	April 2009	Phase 2\|Phase 3
NCT02744092	Alliance Foundation Trials, LLC.\|Patient-Centered Outcomes Research Institute	Cancer\|Venous Thromboembolism\|Deep Vein Thrombosis (DVT)\|Pulmonary Embolism (PE)\|Blood Clot	December 2016	Not Applicable
NCT01390883	GlaxoSmithKline	Cardiovascular Disease	December 2008
NCT00911157	GlaxoSmithKline	Thrombosis, Venous	June 2008	Phase 3
NCT01267305	Shanghai Zhongshan Hospital	Lung Neoplasms\|Esophageal Neoplasms\|Venous Thromboembolism	January 2011	Not Applicable
NCT00320424	GlaxoSmithKline	Thromboembolism	February 16, 2006	Phase 3
NCT01467583	Wayne State University\|GlaxoSmithKline	Venous Thromboembolism	November 2011	Phase 4
NCT00790907	GlaxoSmithKline	Acute Coronary Syndrome	February 2009	Phase 4
NCT01304238	GlaxoSmithKline	Acute HIT II (Heparin-induced Thrombocytopenia Type II)	February 2009
NCT00412464	Children´s Hospital Los Angeles\|FDA Office of Orphan Products Development	Thrombosis\|Heparin-induced Thrombocytopenia	September 2006	Phase 1
NCT01428544	GlaxoSmithKline	Ataxia	March 2012
NCT00443053	GlaxoSmithKline	Thrombosis, Venous	March 2007	Phase 3
NCT00531843	Mary Knudson, M.D.\|GlaxoSmithKline\|University of California, San Francisco	Venous Thromboembolism	December 2007	Phase 2\|Phase 3
NCT00381888	Masonic Cancer Center, University of Minnesota	Cervical Cancer\|Endometrial Cancer\|Fallopian Tube Cancer\|Ovarian Cancer\|Sarcoma\|Thromboembolism\|Vaginal Cancer\|Vulvar Cancer	January 2007	Phase 2
NCT01691495	GlaxoSmithKline	Thrombosis, Venous	October 2012
NCT00256100	Melbourne Health	Renal Failure	June 2004	Not Applicable
NCT04368377	University of Milan\|Fondazione Un Cuore per Milano - a no profit foundation	Pneumonia, Viral\|Corona Virus Infection\|Respiratory Failure\|Embolism and Thrombosis	April 6, 2020	Phase 2
NCT00673439	University of Louisville\|James Graham Brown Cancer Center	Heparin-Induced Thrombocytopenia	November 2007	Phase 2
NCT05001776	National Medical Research Center for Therapy and Preventive Medicine	Superficial Vein Thrombosis\|Endovenous Laser Ablation	August 16, 2021	Phase 4
NCT00346879	Indiana University School of Medicine\|American Society for Bariatric Surgery\|Indiana University	Morbid Obesity	August 2006	Phase 1
NCT00413504	Brigham and Women´s Hospital\|GlaxoSmithKline	Deep Vein Thrombosis\|Pulmonary Embolism	April 2006	Not Applicable
NCT00911300	GlaxoSmithKline	Fibrillation, Atrial	August 2009	Phase 2
NCT01004939	GlaxoSmithKline	Thromboembolism\|Venous Thromboembolism	March 2010
NCT00436787	University of Pittsburgh\|GlaxoSmithKline	Venous Thrombosis\|Pulmonary Embolism	February 2007	Phase 2
NCT00139815	GlaxoSmithKline\|University of Chicago\|Organon\|Sanofi\|Duke University	Thromboembolism	April 2003	Phase 3
NCT01499953	GWT-TUD GmbH\|Bayer	Superficial Vein Thrombosis	April 2012	Phase 3
NCT00894283	Johns Hopkins University\|GlaxoSmithKline	Deep Venous Thrombosis\|Pulmonary Embolism	June 2009	Early Phase 1
NCT04447378	National University of Malaysia	Thromboembolism in the Puerperium	September 1, 2017	Phase 4
NCT01406301	GlaxoSmithKline	Acute Coronary Syndrome	March 2008
NCT00493896	Eastern Virginia Medical School\|GlaxoSmithKline	Venous Thromboembolism	July 2007	Phase 3
NCT01390896	GlaxoSmithKline	Cardiovascular Disease	September 2009
NCT00843492	GlaxoSmithKline	Thrombosis, Venous	December 2008	Phase 3
NCT00483600	Duke University\|GlaxoSmithKline	Kidney Diseases	August 2007	Not Applicable
NCT00424281	Wayne State University\|GlaxoSmithKline	ICU Patients 18 Years or Older.	February 2007
NCT00927602	Università degli Studi dell´Insubria	Medical Patients\|Renal Insufficiency	April 2009	Phase 4
NCT00555438	Centre Hospitalier Universitaire de Saint Etienne\|GlaxoSmithKline	Major Orthopaedic Surgery and Renal Impairment	June 2007	Phase 4
NCT01857583	Daiichi Sankyo Co., Ltd.\|Daiichi Sankyo, Inc.	Venous Thromboembolism	March 2012	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 125 mg/mL ( 72.33 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.5787 mL	2.8934 mL	5.7868 mL
5 mM	0.1157 mL	0.5787 mL	1.1574 mL
10 mM	0.0579 mL	0.2893 mL	0.5787 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 100 mg/mL (57.87 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

[1] Bauer KA. et al. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S14-7.
[2] Ben-Hadj-Khalifa S, et al. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul Fibrinolysis. 2011 Jul;22(5):369-73.

Synonyms

α-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→4)-O-β-D-glucopyranuronosyl-(1→4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1→4)-2-deoxy-2-(sulfoamino)-, 6-(hydrogen sulfate), sodium salt (1:10)

IC 851589

SR 90107A

Fondaparinux sodium

Arixtra

Xantidar

Fondaparin sodium

Org 31540

IC 85158

Fondaparinux

Fondaparin

Quixidar

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart